EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Impact of Biologics on Oscillometry Defined Small Airway Dysfunction in Uncontrolled Asthma

Robert Greig iD, Philipp Suter, Rory Chan, Brian Lipworth iD

Clinical & Experimental Allergy · 2026-07 · 56 (7) · 710-717

DOI: 10.1111/cea.70349 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 24.05.2026. Verfasst von Robert Greig und 3 weiteren Autor:innen. Beteiligte Einrichtung: Scottish Centre for Respiratory Research, University of Dundee, Dundee, UK. Hauptthemen laut MEDLINE: Asthma, Biological Products, Oscillometry, Anti-Asthmatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small airways dysfunction (SAD) is a recognised treatable trait within severe asthma, associated with worse symptom control and increased exacerbations. It can be measured using forced oscillometry technique (FOT). FOT is an effective and effort‐independent method of measuring peripheral lung resistance and compliance. Type 2 inflammation can affect the small airways via eosinophilic inflammation, mucus plugging and smooth muscle inflammation. These are all potential targets of monoclonal antibody therapy. Clinical trials have shown that mepolizumab, dupilumab and tezepelumab all effect both significant and clinically meaningful improvements in oscillometry‐defined SAD; however, benralizumab does not. Furthermore, in indirect matched head‐to‐head comparisons, dupilumab exerts greater improvements compared to either benralizumab or tezepelumab. Future research should consider oscillometry‐defined SAD being incorporated as a key clinical outcome in phase 2 studies as new monoclonal antibodies are developed, such as bispecifics, especially both dual upstream (IL33/TSLP) or downstream blockade (IL4/5/13).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaBiological ProductsOscillometryAnti-Asthmatic AgentsHumansAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

asthmabenralizumabbiologicsdupilulmabmepolizumabmonoclonal antibodiesoscillometrysmall airways dysfunctiontezepelumab

Substanzen

Biological ProductsAnti-Asthmatic AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Scottish Centre for Respiratory Research, University of Dundee, Dundee, UK.

ORCID-Profile: Robert Greig, Brian Lipworth

Zitieren

APA

Greig, R., Suter, P., Chan, R., & Lipworth, B. (2026). Impact of Biologics on Oscillometry Defined Small Airway Dysfunction in Uncontrolled Asthma. Clinical & Experimental Allergy, 56(7), 710-717. https://doi.org/10.1111/cea.70349

Vancouver

Greig R, Suter P, Chan R, Lipworth B. Impact of Biologics on Oscillometry Defined Small Airway Dysfunction in Uncontrolled Asthma. Clinical & Experimental Allergy. 2026;56(7):710-717. doi:10.1111/cea.70349

BibTeX
@article{Greig2026,
  author = {Greig, Robert and Suter, Philipp and Chan, Rory and Lipworth, Brian},
  title = {Impact of Biologics on Oscillometry Defined Small Airway Dysfunction in Uncontrolled Asthma},
  journal = {Clinical & Experimental Allergy},
  year = {2026},
  volume = {56},
  number = {7},
  pages = {710--717},
  doi = {10.1111/cea.70349}
}
Kostenlos starten →